Lomitapide for homozygous familial hypercholesterolaemia

The Lancet

Volumn 381, Issue 9860, 2013, Pages 7-8

  Raal, Frederick J ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRANSFER PROTEIN; MIPOMERSEN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT;

EID: 84871998570     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61845-5     Document Type: Note

References (12)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 8th edn. New York: McGraw-Hill, 2001: 2863-913.
2. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223: 262-68.
3. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011; 124: 2202-07.
4. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
5. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997; 1345: 136-50.
6. Di Leo E, Lancellotti S, Penacchioni JY, et al. Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. Atherosclerosis 2005; 180: 311-18.
7. Cuchel M, Meagher EA, Theron HdT, et al, for the Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2012; published online Nov 2. http://dx.doi.org/10.1016/S0140- 6736(12)61731-0.
8. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with non-alcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-38.
9. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380: 29-36.
10. Grundy SM. Is lowering low-density lipoprotein an eff ective strategy to reduce cardiac risk? Circulation 2008; 117: 569-73.
11. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
12. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.